Skye Bioscience, Inc. (SKYE)
| Market Cap | 14.59M -85.0% |
| Revenue (ttm) | n/a |
| Net Income | -50.49M |
| EPS | -1.28 |
| Shares Out | 35.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,646,349 |
| Open | 0.5703 |
| Previous Close | 0.5015 |
| Day's Range | 0.4128 - 0.5857 |
| 52-Week Range | 0.2760 - 4.9900 |
| Beta | 2.99 |
| Analysts | Buy |
| Price Target | 7.60 (+1,730.88%) |
| Earnings Date | Aug 17, 2026 |
About SKYE
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in S... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SKYE stock is "Buy." The 12-month stock price target is $7.6, which is an increase of 1,730.88% from the latest price.
News
Skye Bioscience Inc trading halted, news pending
08:39 EDT Skye Bioscience (SKYE) Inc trading halted, news pending
Skye Bioscience to acquire Redx Pharma via scheme of arrangement
Skye Bioscience (SKYE) and Redx Pharma announced that they have entered into a definitive transaction agreement. Under the Transaction Agreement, Skye will acquire the entire issued share capital of R...
Skye Bioscience Inc trading resumes
10:00 EDT Skye Bioscience (SKYE) Inc trading resumes
Skye Bioscience Quarterly report: Q2 2026
Skye Bioscience has published its Q2 2026 quarterly earnings report on August 14, 2026.
Skye Bioscience Transcript: M&A announcement
The merger forms Fibrx Therapeutics, a Nasdaq-listed fibrosis-focused company with a $125M financing and a pipeline led by RXC008 for fibrostenotic Crohn's disease. Skye shareholders retain upside via contingent value rights and a minority stake.
Skye Bioscience Press release: M&A announcement
Skye Bioscience issued a press release on August 14, 2026, disclosing material business information to investors.
Skye Bioscience Slides: M&A announcement
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company's lead program will be RXC008, Redx's GI-restricted ...
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Transcript: AGM 2026
The meeting established a quorum and approved all proposals, including director elections, auditor ratification, an increase in authorized shares, and executive compensation. No questions were raised by stockholders during the Q&A session.
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic h...
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience price target lowered to $6 from $13 at Piper Sandler
Piper Sandler lowered the firm’s price target on Skye Bioscience (SKYE) to $6 from $13 and keeps an Overweight rating on the shares. The firm notes Skye ended Q1 2026…
Skye Bioscience reports Q1 EPS (32c), consensus (32c)
“Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of…
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-...
Skye Bioscience Quarterly report: Q1 2026
Skye Bioscience has published its Q1 2026 quarterly earnings report on May 11, 2026.
Skye Bioscience Earnings release: Q1 2026
Skye Bioscience released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Skye Bioscience Slides: Corporate presentation
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other m...
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Proxy statement: Proxy filing
Skye Bioscience filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Skye Bioscience Slides: Corporate presentation
Skye Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on April 3, 2026.
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Topline safety and pharmacokinetic data expected in Q4 2026; an independent Data Monitoring Committee is overseeing the study Topline safety and pharmacokinetic data expected in Q4 2026; an independen...